

Cover Story
By Matthew Bin Han Ong
The NCI-60, a panel of 60 cancer cell lines that have become the Rosetta Stone for the development of anticancer drugs, may be entering its twilight years as NCI develops new, and more expansive, patient-derived xenografts, or PDX models.
In Brief


Funding Opportunities
Drugs & Targets


Trending Stories
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- Pediatric cancer five-year survival rate has increased dramatically, AACR says in inaugural Pediatric Cancer Progress Report
- Brown University reaches agreement with Trump administration to restore funding
- Antonio Wolff, Mikala Egeblad named co-directors of Johns Hopkins Kimmel Cancer Center Breast and Gynecologic Cancer Program
- In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook
- Anthony Letai pledges to ensure stability for extramural and intramural cancer science











